Leonardo Biosystems | GenomeWeb

Leonardo Biosystems

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

People in the News

Premium

Arrowhead Research has appointed Bruce Given as its COO.

People in the News

Premium

Mauro Ferrari

Leonardo, which had been expecting the funding, intends to use the money to ramp up its operations with the goal of securing industry partnerships around its so-called multi-stage delivery approach.

While the company may at some point down the road dip its toes into the drug-development waters, "initially, I don't see us having any in-house discovery efforts," Leonardo CEO Bruce Given said.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.